DigestRedComo funciona
Red
/
Empresas
Ne
No verificado

Newron Pharmaceuticals S.p.A.

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaMedicina - VariosSalud

23 Comunicados de prensa

Ver todos los comunicados de prensa
24/03/2026
Telefonía
Mercado de valores
Ciencia
Psiquiatría
Medicina - Varios
Biotecnología
Sanidad
Farmacéutica
Salud
Newron Presents 2025 Financial Results and Provides 2026 Outlook
Fuente
Newron Pharmaceuticals S.p.A.
Editor
Business Wire
1.00
0
20/03/2026
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Eventos
Industria
Newron to Present at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
Fuente
Newron Pharmaceuticals S.p.A.
Editor
Business Wire
1.00
0
19/03/2026
Mercado laboral
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Newron Announces Agreement With the European Investment Bank (EIB) to Extend the Near-Term Tranche Repayment Dates of Its 2018 Finance Contract
Fuente
Newron Pharmaceuticals S.p.A.
Editor
Business Wire
1.00
0
18/03/2026
Mercado laboral
Biotecnología
Farmacéutica
Finanzas
Sanidad
Salud
Administración de Empresas
Banca
Asociaciones/Profesionales
Newron Announces Nominations to Its Board of Directors at Upcoming Annual General Meeting
Fuente
Newron Pharmaceuticals S.p.A.
Editor
Business Wire
1.00
0
16/02/2026
Mercado de valores
Industria
Ciencia
Biotecnología
Farmacéutica
Salud
Psiquiatría
Medicina - Varios
Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program
Fuente
Newron Pharmaceuticals S.p.A.
Editor
Business Wire
1.00
0
03/02/2026
Industria
Ciencia
Higiene alimentaria
Medicina - Varios
Biotecnología
Salud
Farmacéutica
Sanidad
Newron Notes Publication Highlighting Clinically Meaningful Benefits of Evenamide as an Adjunctive Treatment in Schizophrenia
Fuente
Newron Pharmaceuticals S.p.A.
Editor
Business Wire
1.00
0
07/01/2026
Mercado laboral
Industria
Psiquiatría
Salud
Medicina - Varios
Farmacéutica
Biotecnología
EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan
Fuente
Newron Pharmaceuticals S.p.A.
Editor
Business Wire
1.00
0
06/01/2026
Industria
Psiquiatría
Salud
Ciencia
Farmacéutica
Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent
Fuente
Newron Pharmaceuticals S.p.A.
Editor
Business Wire
1.00
0
22/12/2025
Ciencia
Biotecnología
Farmacéutica
Salud
Psiquiatría
Medicina - Varios
Eventos
Newron to Host Investor and Partnering Meetings During the J.P. Morgan Healthcare Conference Week
Fuente
Newron Pharmaceuticals S.p.A.
Editor
Business Wire
1.00
0
08/12/2025
Industria
Psiquiatría
Higiene alimentaria
Salud
Medicina - Varios
Farmacéutica
Newron Announces the US Initiation of Its ENIGMA-TRS 2 Phase III Global Clinical Study With Evenamide as an Add-On Therapy for Patients With Treatment-Resistant Schizophrenia (TRS)
Fuente
Newron Pharmaceuticals S.p.A.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0